Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study

Introduction: Around 3–5% of non-small cell lung cancers (NSCLC) are ALK-positive. Crizotinib was the first approved ALK inhibitor from clinical trials. However, there are less data on the utilization and patient outcomes associated with crizotinib in real-world clinical practice. Methods: This was...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Craig, Masters, Elizabeth T., Black-Shinn, Jenny, Boyd, Marley, Mardekian, Jack, Espirito, Janet L., Chioda, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025021/
https://www.ncbi.nlm.nih.gov/pubmed/29844259
http://dx.doi.org/10.3390/jcm7060129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025021/
https://www.ncbi.nlm.nih.gov/pubmed/29844259
http://dx.doi.org/10.3390/jcm7060129

Ejemplares similares